Oral anticancer therapy: Management of drug interactions

Authors

Britny G. Rogala, University of Rhode Island
M. Charpentier, University of Rhode Island
Michelle K. Nguyen, New York Presbyterian Hospital
Kaitlin M. Landolf, UPMC Presbyterian
Lamya Hamad, Roswell Park Cancer Institute
Kelly M. Gaertner, West Penn Allegheny Health System

Document Type

Article

Date of Original Version

2-1-2019

Abstract

Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management.

Publication Title, e.g., Journal

Journal of Oncology Practice

Volume

15

Issue

2

Citation/Publisher Attribution

Rogala, Britny G., M. Charpentier, Michelle K. Nguyen, Kaitlin M. Landolf, Lamya Hamad, and Kelly M. Gaertner. "Oral anticancer therapy: Management of drug interactions." Journal of Oncology Practice 15, 2 (2019): 81-90. doi: 10.1200/JOP.18.00483.